PARP inhibitor maintenance treatment for newly diagnosed ovarian cancer patients: a real-world study from China

PurposeThis study evaluated the efficacy and safety in a real-world population of epithelial ovarian cancer (EOC) treated with poly (ADP-ribose) polymerase inhibitor (PARPi) as first-line maintenance therapy in the largest gynecologic oncology center in Western China.MethodsThis study included patie...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Jinghong Chen, Mengpei Zhang, Kemin Li, Yuanqiong Duan, Jing Zeng, Qingli Li, Danqing Wang, Liang Song, Qintong Li, Rutie Yin
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2024-02-01
Edice:	Frontiers in Oncology
Témata:	ovarian cancer poly (ADP-ribose) polymerase inhibitors progression-free survival adverse events real-world study
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1336616/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!